| 06/02 | Novartis : ESG Update Q4 2022 | PU |
| 06/02 | Patients with hidradenitis suppurativa experienced sustained efficacy and symptom impro.. | AQ |
| 06/02 | Sandoz Biologics License Application for proposed biosimilar denosumab accepted by US F.. | GL |
| 04/02 | Patients with hidradenitis suppurativa experienced sustained efficacy and symptom impro.. | GL |
| 01/02 | Novartis : Q4 Earnings Snapshot | AQ |
| 01/02 | Novartis : Condensed financial report | PU |
| 01/02 | Novartis : Annual Report 2022 (SIX filing) | PU |
| 01/02 | Novartis : 2022 Financial Results | PU |
| 01/02 | Novartis : The report | PU |
| 01/02 | Novartis continues to grow with further core margin expansion and achieves important in.. | GL |
| 30/01 | Sandoz receives positive CHMP opinion for citrate-free high concentration formulation o.. | GL |
| 27/01 | Novartis : provides update on Phase III STAND trial assessing crizanlizumab | PU |
| 24/01 | Sandoz announces agreement to acquire leading antifungal agent Mycamine from Astellas, .. | AQ |
| 24/01 | Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas,.. | GL |
| 11/01 | Neurotech Pharmaceuticals, Inc. Expands Executive Team with the Appointment of Scott Hu.. | AQ |
| 10/01 | China’s Porton to set up biotech park in Slovenia’s Menges | AQ |
| 04/01 | CJEU Issues Guidance On When Parallel Importers Can Rebrand Generics As Branded Medicin.. | AQ |
| 2022 | An Arrow Through Declaratory Relief? | AQ |
| 2022 | Case Analysis : Teva UK Ltd And Anor v Novartis AG And Anor | AQ |
| 2022 | Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to ILEVRO, NEVANAC, VIGAM.. | AQ |
| 2022 | Novartis receives European Commission approval for Pluvicto as the first targeted radio.. | AQ |
| 2022 | Novartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational.. | GL |
| 2022 | Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib | AQ |
| 2022 | Novartis investigational iptacopan provides clinically meaningful increases in hemoglob.. | GL |
| 2022 | MorphoSys Out Licenses Pre-Clinical Oncology Program | AQ |
| 2022 | Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggre.. | GL |
| 2022 | Novartis PluvictoTM shows statistically significant and clinically meaningful radiograp.. | GL |
| 2022 | European Court Of Justice Issues Lan : No Repackaging/Rebranding As The Originator Referen.. | AQ |
| 2022 | Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study f.. | AQ |
| 2022 | Novartis : and Medicines for Malaria Venture announce decision to move to Phase 3 study fo.. | PU |
| 2022 | Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 da.. | GL |
| 2022 | New long-term Leqvio® (inclisiran) data from Novartis show sustained efficacy and safet.. | GL |
| 2022 | Sandoz announces further investment in key manufacturing facility in Austria, to suppor.. | GL |
| 2022 | Actinium Appoints Seasoned Leader Caroline Yarbrough as Chief Commercial Officer to Spe.. | AQ |
| 2022 | Biogen Seeks A Preliminary Injunction In Natalizumab BPCIA Case Against Sandoz | AQ |
| 2022 | Novartis : Q3 Earnings Snapshot | AQ |
| 2022 | Novartis : Financial Results – Q3 2022 | PU |
| 2022 | Novartis maintains growth momentum and confirms FY'22 Group guidance | GL |
| 2022 | Novartis investigational oral monotherapy iptacopan demonstrates clinically meaningful .. | GL |
| 2022 | Novartis : Q3 2022 Results Investor presentation | PU |
| 2022 | Novartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PS.. | GL |
| 2022 | World Sight Day 2022 : Raising awareness on the importance of eye health | PU |
| 2022 | Novartis : The FY 2021 Novartis environmental indicators (PDF 0. | PU |
| 2022 | Malaria Pipeline Landscape Analysis of 15+ Companies by DelveInsight | AQ |
| 2022 | Pm(noc) Regulations : Five-year Anniversary Of Major Amendments | AQ |
| 2022 | Monsenso participates in new, large innovation project | AQ |
| 2022 | Sandoz Granted Leave To Add New Allegations On Condition Of Trial Adjournment And Exten.. | AQ |
| 2022 | Novartis unveils new focused strategy, underpinned by eight potential multi-billion dol.. | GL |
| 2022 | Novartis plans to petition the U.S. Supreme Court to uphold validity of the Gilenya® (f.. | GL |
| 2022 | Tysabri® (Natalizumab) Litigation Begins | AQ |
| 2022 | Sandoz announces further progress on its biosimilar pipeline, with release of positive .. | GL |
| 2022 | Sandoz announces further progress on its biosimilar pipeline, with release of positive .. | AQ |
| 2022 | Novartis statement regarding competition authority investigation into assertion of a pa.. | GL |
| 2022 | Biogen Files Sealed Complaint Against Sandoz And Polpharma Biologics Regarding Natalizu.. | AQ |
| 2022 | Novartis Hematology : Working to help ensure patients are getting the access they need | PU |
| 2022 | Novartis : invests in early technical development capabilities for next-generation biother.. | PU |
| 2022 | Novartis Cosentyx® shows clinically meaningful symptom improvements in patients with hi.. | AQ |
| 2022 | Novartis Cosentyx® shows clinically meaningful symptom improvements in patients with hi.. | GL |
| 2022 | Novartis Kisqali® adds one more year of survival benefit for broadest set of patients, .. | GL |
| 2022 | Novartis Hematology : Working to help ensure patients are getting the access they need | PU |
| 2022 | Novartis highlights depth of immunology pipeline with novel data at key upcoming intern.. | GL |
| 2022 | The Sound Of Silence – The Importance Of Knowing What Your Invention Is Not | AQ |
| 2022 | Novartis appoints Fiona Marshall, Ph.D., President of the Novartis Institutes for BioMe.. | GL |
| 2022 | Kaiku Health to improve cancer care through partnership with global medicines company | AQ |
| 2022 | Novartis presents new data in breast and prostate cancer at ESMO | GL |
| 2022 | Novartis looks at spinning out generics unit | AQ |
| 2022 | Branaplam : VIBRANT-HD Study Update | PU |
| 2022 | Swiss drugmaker Novartis to spin off generics unit Sandoz | AQ |
| 2022 | Novartis announces intention to separate Sandoz business to create a standalone company.. | GL |
| 2022 | Novartis : Download the Novartis 2030 Environmental Sustainability Strategy | PU |
| 2022 | Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant.. | GL |
| 2022 | Australia's Cell and Gene Catalyst moves ahead | AQ |
| 2022 | Sandoz & Polpharma Announce FDA And EMA Acceptance Of Applications For Natalizumab Bios.. | AQ |
| 2022 | Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab acc.. | GL |
| 2022 | Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab acc.. | AQ |
Google
Twitter
Facebook
Apple
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Rapport
